Cytosorbents ( (CTSO) ) has shared an announcement.
CytoSorbents Corporation announced the postponement of its earnings release, originally scheduled for March 6, 2025, to March 25, 2025, following the passing of its Vice President and Corporate Controller, James E. Cason, Jr. The company reaffirmed its preliminary financial results for 2024, expecting significant growth in product revenue and gross margins. The delay aims to ensure a thorough completion of the annual audit. CytoSorbents also continues to anticipate regulatory decisions on its DrugSorb™-ATR marketing applications in 2025, which are under review by the U.S. FDA and Health Canada.
More about Cytosorbents
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The company’s proprietary technologies use biocompatible, highly porous polymer beads to remove toxic substances from blood and other bodily fluids. Their products are used in various applications, including the removal of blood thinners during cardiothoracic surgery and inflammatory agents in critical illnesses. CytoSorbents’ lead product, CytoSorb®, is approved in the European Union and distributed in 76 countries worldwide.
YTD Price Performance: 15.22%
Average Trading Volume: 280,012
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $58.12M
Find detailed analytics on CTSO stock on TipRanks’ Stock Analysis page.